retatrutide triple agonist obesity trial Targeting Glp-1 Stock Photo 2639191569 Another Promising Medication (Retatrutide) for

These positive results indicate that the change in myocardial cells may not be the primary driver of HFpEF

The lead researcher of the study and doctors share how these side effects can interfere with exercise and how to adjust your training when taking a GLP-1 medication

10.1056/NEJMoa1603827 54 MarsoS

A recent study found no correlation between short- and long-acting of GLP-1 RA, dose, and duration of use with a percentage of patients in all categories experiencing residual gastric contents

Here are the protocols, populations, and published results

368 Since GLP-1R is expressed in thyroid C cells and GLP-1 directly stimulates the secretion of calcitonin, which is a potent inhibitor of bone resorption in osteoclasts, GLP-1 may contribute to the nutrient-mediated reduction in bone resorption